UPDATE: Cowen and Company Upgrades OraSure Technologies to Outperform, Reiterates $6.60 PT Following Reduced Launch Expectations

In a report published Tuesday, Cowen and Company analyst Shaun Rodriguez upgraded the rating on

from Market Perform to Outperform, and reiterated the $6.60. In the report, Cowen and Company noted, “We believe investor expectations for HIV-OTC launch have been appropriately reduced. With shares trading 60% below levels 1 yr ago, we believe risk/reward is favorable with our positive views on HCV and Genotek and improved base business visibility. Upgrade to Outperform (from Market Perform).” OraSure Technologies closed on Monday at $4.62.